Release Details

PARIS, FRANCE, September 2, 2022 – 8:30 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284 – ABVX) (the “Company”), a phase 3 clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces the availability of an amendment to its 2022 Universal Registration Document filed with the French Autorité des marchés financiers (“AMF”) on April 28, 2022 under number D.22-0372 and of a listing prospectus approved by the AMF under number 22-368 on September 2, 2022, in the context of its reserved oversubscribed capital increase of approximately EUR 46 million.

The prospectus is composed of:

• the 2022 Universal Registration Document filed with the AMF on April 28, 2022 under number 22-0372;
• the amendment of the 2022 Universal Registration Document filed with the AMF on September 2, 2022 under number 22-0372-A01;
• a securities note (note d’opération); and
• the summary of the prospectus.

These documents are available on the websites of the Company (www.abivax.com) and the AMF (www.amf-france.org).

*****

About Abivax (www.abivax.com)

Abivax, a phase 3 clinical stage biotechnology company, is developing novel therapies that modulate the body’s natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, obefazimod (ABX464) to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.

Contacts

Disclaimer

This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.